Transgene Biotek Limited has officially communicated to BSE that Regulation 57 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 does not apply to the company for the quarter ended March 31, 2026. The notification, dated April 13, 2026, was addressed to the General Manager of BSE's Department of Corporate Services.

Regulatory Compliance Status

The company's non-applicability status stems from the fact that Transgene Biotek Limited has not issued any non-convertible securities. This fundamental aspect exempts the company from the specific regulatory requirements outlined in SEBI LODR Regulation 57.

Official Communication Details

The formal notification was submitted under the subject "Compliance under regulation 57 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 for the quarter ended 31.03.2026." The company specifically stated that the regulation is not applicable since there are no non-convertible securities for which interest, dividend, or principal is payable during the quarter.

Compliance Requirements Assessment

The company provided a clear assessment of the regulatory compliance requirements for Q4 FY26:

Management Authorization

The formal notification was signed by Dr. K Koteswara Rao, Chairman & Managing Director of Transgene Biotek Limited. The communication was directed to BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai, requesting the exchange to take the information on record.

This regulatory filing ensures transparency and compliance with SEBI's disclosure requirements, even when specific regulations are not applicable to the company's current business structure and securities profile.

Transgene Biotek Limited has filed a mandatory compliance certificate with the Bombay Stock Exchange (BSE) confirming proper maintenance of its share transfer facility as required under securities regulations.

Regulatory Compliance Filing

The company submitted the compliance certificate on April 13, 2026, addressed to the General Manager of BSE's Listing Compliance Department. The filing was made pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Share Transfer Agent Details

The certificate confirms that Transgene Biotek Limited maintains both physical and electronic share transfer facilities through its appointed registrar and share transfer agent, Bigshare Services Private Limited. This arrangement ensures proper handling of share transfer activities for the company's shareholders.

Compliance Significance

The filing represents routine regulatory compliance for listed companies under SEBI LODR Regulations. The certificate was duly signed by authorized representatives from both Transgene Biotek Limited and Bigshare Services Private Limited, confirming the ongoing maintenance of share transfer facilities as mandated by securities regulations.

This compliance filing demonstrates the company's adherence to mandatory disclosure requirements and ensures transparency in share transfer operations for investors and regulatory authorities.